Acta Pharmaceuticals announced USD 24 million in total seed financing on 15 October 2026. The Boston company is developing therapies for earlier intervention in Alzheimer's disease, building on scientific founder Dr Rudolph Tanzi's research. Its lead candidate, GSM-779690T, is an oral gamma-secretase modulator intended to alter production of amyloid beta proteins. Acta plans a Phase 1 study assessing safety, tolerability and pharmacokinetics in healthy volunteers. Shareholders include Alzheimer's Disease Research Foundation, Dolby Family Ventures and Gamma Bio Investors, but no lead was named. The total seed figure is distinct from historical research support. Clinical safety and efficacy remain unestablished.
Acta Pharmaceuticals announces USD 24m in total seed financing
Boston company advances an investigational Alzheimer's disease program

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


